AstraZeneca PLC’s recent and coming launches of new drugs and its expanding pipeline, along with a big presence in China and the promising vaccine that is being developed against SARS-CoV-2 virus in partnership with Oxford University, should ensure keen investor interest when the UK-based drugmaker reports second quarter and half-year results on 30 July.
The company has returned to financial growth on the back of a rejuvenated pipeline and new drug offerings that are...








